Armata Pharmaceuticals Promotes David House to Chief Financial Officer

On July 17, 2026, Armata Pharmaceuticals, Inc. announced the promotion and appointment of David House as the Company’s Chief Financial Officer. Mr. House has served as the Senior Vice President of Finance and principal financial officer since August 2024. Under his new employment letter agreement, Mr. House will receive an annual base salary of $371,315 and a target annual bonus of 50% of his base salary. Additionally, he is eligible for annual equity awards starting in 2026, with an intended grant date fair value of approximately $300,000. The agreement includes severance provisions of 12 months' base salary for termination without cause or resignation for good reason, as well as accelerated equity vesting in the event of an involuntary termination related to a change in control. Concurrently, the Company amended the employment agreement of Pierre Kyme, Chief Business Officer, to align his 'change in control' definitions with those in Mr. House’s agreement. Both agreements are governed by California law.